Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jason Peter

Physical Medicine & Rehabilitation Troy, MI Doctor of Osteopathy

NPI 1851581789 CMS profile 266359

2885 E Long Lake Rd Ste A, Troy, MI 48085

Open in the dashboard

General payments

$20,457

424 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jason Peter of Troy, MI is reported in the CMS Open Payments database as having received $20,457 across 424 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Physical Medicine & Rehabilitation profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $818 31
2024 General $1,026 35
2023 General $3,012 52
2022 General $3,664 52
2021 General $4,210 74
2020 General $3,136 86
2019 General $4,590 94

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jason Peter
  • Physical Medicine & Rehabilitation median
  • Middle half of Physical Medicine & Rehabilitation
  • National median

In program year 2025, general payments to Jason Peter were reported at $818. Among 4,146 Physical Medicine & Rehabilitation profiles paid that year, the median was $139 and the middle half received between $48 and $410.

Show as a table
Year Jason Peter Physical Medicine & Rehabilitation median Middle half National median
2019 $4,590 $133 $45–$390 $163
2020 $3,136 $88 $29–$272 $114
2021 $4,210 $116 $33–$360 $132
2022 $3,664 $123 $40–$378 $149
2023 $3,012 $131 $43–$396 $160
2024 $1,026 $141 $45–$409 $164
2025 $818 $139 $48–$410 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Nevro Corp. $4,724 79 payments
  2. Medtronic, Inc. $4,461 44 payments
  3. Abbott Laboratories $1,509 33 payments
  4. Relievant Medsystems, Inc. $1,478 13 payments
  5. Boston Scientific Corporation $1,427 46 payments
  6. Vertiflex, Inc. $1,339 16 payments
  7. Medtronic USA, Inc. $981 20 payments
  8. Vertos Medical, Inc. $763 28 payments
  9. SPR Therapeutics, Inc $741 12 payments
  10. Collegium Pharmaceutical, Inc. $533 30 payments
  11. Other $2,500 103 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $16,569 410 payments
  2. Travel and Lodging $3,888 14 payments
Products named General payments · program years 2019–2025
  1. Omnia $2,336 36 payments
  2. Senza Spinal Cord Stimulation System $2,128 39 payments
  3. INTELLIS ADAPTIVESTIM $2,007 18 payments
  4. SYNCHROMEDII $1,990 16 payments
  5. Superion ISS $1,339 16 payments
  6. Proclaim Family of SCS IPGs $926 17 payments
  7. Intracept Pain $894 5 payments
  8. Intracept Pain $894 5 payments
  9. INTELLIS $870 10 payments
  10. SPRINT PNS System $741 12 payments
  11. Other $8,073 282 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 16 drugs

Part D claims

476

Median for Interventional Pain Management: 1,220

Drug cost

$10,956

Median for Interventional Pain Management: $39,344

Branded share of claims

42.2%

Median for Interventional Pain Management: 34.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Buprenorphine Generic 22 $3,836
Naloxone Hcl Generic 33 $2,029
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 111 $1,411
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 41 $686
Pregabalin Generic 34 $664
Acetaminophen-Codeine Acetaminophen With Codeine Brand 14 $418
Morphine Sulfate Er Morphine Sulfate Brand 19 $364
Naproxen Generic 36 $326
Baclofen Generic 26 $299
Methadone Hcl Generic 12 $190

The 10 drugs with the highest cost, of 16 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,476 Part D prescribers listed as Interventional Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 52 billing codes

Paid by Medicare

$352,694

Of which drugs: $19

Medicare patients

485

Average age 68

Services billed

3,387

306 women, 179 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 73%
Diabetes 36%
Depression 32%
Ischemic heart disease 31%
COPD 26%
Chronic kidney disease 23%
Heart failure 19%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 20 232 $17

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

4 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BELBUCA
  • Collegium Pharmaceutical, Inc. $85
$85 — —
XTAMPZA
  • Collegium Pharmaceutical, Inc. $78
$78 — —
PURIFIED CORTROPHIN GEL
  • ANI Pharmaceuticals, Inc. $21
$21 — —
RELISTOR
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $15
$15 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

424 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physical Medicine & Rehabilitation in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record